Speaker
Description
Background: Oesophageal cancer is a malignant disease that accounts for the seventh major cause of cancer-associated death worldwide. Hypocrellin B, a natural photosensitizer, has been employed for photodynamic therapy for various neoplastic diseases. However, studies that utilize hypocrellin B-based- photodynamic therapy on oesophageal cancer are limited. This current study examined the in vitro effects of hypocrellin B-based-photodynamic therapy on human oesophageal cancer cells.
Materials and methods: Human oesophageal cancer HKESC-1 cells were grouped into non-photodynamic and photodynamic therapy groups. Both groups were treated with varying concentrations of hypocrellin B. After four hours, the photodynamic therapy category was irradiated at a fluency of 5 J/cm2 and a wavelength of 470nm. Twenty-four-hour post-irradiation cell viability, lactate dehydrogenase (LDH) release and damage to the mitochondrial and nuclear morphological assessments were performed.
Results: Treatment with hypocrellin B-mediated photodynamic therapy significantly reduced the amount of ATP/viability of HKESC-1 cells, and the amount of LDH released was notably higher in the photodynamic therapy group. Mitochondrial membrane potential was impaired, and nuclear condensation was markedly observed in the hypocrellin B-mediated photodynamic therapy.
Conclusion: Hypocrellin-B mediated photodynamic therapy demonstrated remarkable anticancer activities in oesophageal cancer HKESC-1 cells.
| Apply for student award at which level: | None |
|---|---|
| Consent on use of personal information: Abstract Submission | Yes, I ACCEPT |
